Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Highnoon LaboratoriesKAR:HINOON -1.24%96 Return-on-Tangible-Asset is 20.69% as of Mar. 2026, which is 6% below its 10-year median of 21.91. GuruFocus rates KAR:HINOON with a GF Score™ of 96/100 and a GF Value™ of ₨1,035.66 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Highnoon Laboratories ranks better than 95.03% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Highnoon Laboratories's annualizedNet Income for the quarter that ended in Mar. 2026 was ₨4,192 Mil. Highnoon Laboratories's average total tangible assets for the quarter that ended in Mar. 2026 was ₨20,262 Mil. Therefore, Highnoon Laboratories's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 20.69%.
The historical rank and industry rank for Highnoon Laboratories's Return-on-Tangible-Asset or its related term are showing as below:
KAR:HINOON'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 19.1 Med: 21.91 Max: 25.64
Current: 21.61
During the past 13 years, Highnoon Laboratories's highest Return-on-Tangible-Asset was 25.64%. The lowest was 19.10%. And the median was 21.91%.
KAR:HINOON's Return-on-Tangible-Asset is ranked better than 95.03% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 2.96
vs KAR:HINOON: 21.61
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Highnoon Laboratories Return-on-Tangible-Asset Related Terms
Highnoon Laboratories Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Highnoon Laboratories's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:HINOON vs LLY, JNJ, ABBV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, Highnoon Laboratories's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Highnoon Laboratories Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Highnoon Laboratories's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Highnoon Laboratories's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 20.69% mean?
Highnoon Laboratories (KAR:HINOON) has a Return-on-Tangible-Asset of 20.69% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Highnoon Laboratories and its competitors. This is near median its historical median of 21.91. Over the past decade, Highnoon Laboratories' Return-on-Tangible-Asset has ranged from 19.10 to 25.64. According to the industry distribution chart, Highnoon Laboratories ranks #50 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 5%.
Is Highnoon Laboratories' Return-on-Tangible-Asset too high?
Highnoon Laboratories' current Return-on-Tangible-Asset of 20.69% is near median its 10-year median of 21.91. Over the past 10 years, this metric has ranged from a low of 19.10 to a high of 25.64. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.96. Highnoon Laboratories' value of 20.69% is 599% above this industry median. Based on the distribution chart, Highnoon Laboratories ranks #50 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Highnoon Laboratories has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Highnoon Laboratories' Return-on-Tangible-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Highnoon Laboratories ranks #50 out of 1006 companies for Return-on-Tangible-Asset. This places Highnoon Laboratories in the top 5% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.96. Highnoon Laboratories' value of 20.69% is 599% above this benchmark. Historically, Highnoon Laboratories' own Return-on-Tangible-Asset has ranged from 19.10 to 25.64 over the past decade. While the company's 10-year median is 21.91 vs. the industry median of 2.96, Highnoon Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.96, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Highnoon Laboratories's current Return-on-Tangible-Asset of 20.69% is 599% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Highnoon Laboratories and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Highnoon Laboratories's current Return-on-Tangible-Asset is 20.69%, which is near median its own 10-year median of 21.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Highnoon Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Highnoon Laboratories (KAR:HINOON) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,035.66, compared to a current price of ₨975.15 — trading 5.8% below its estimated fair value. The current Return-on-Tangible-Asset is 20.69%, which is near median its 10-year median of 21.91 and 599% above the Drug Manufacturers industry median of 2.96. Highnoon Laboratories' overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Highnoon Laboratories (KAR:HINOON), the current Return-on-Tangible-Asset is 20.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Highnoon Laboratories (KAR:HINOON) Overvalued in 2026?
Based on GuruFocus' analysis, Highnoon Laboratories stock appears to be undervalued.
The current stock price of ₨975.15 is trading 5.8% below its estimated GF Value™ of ₨1,035.66.
GuruFocus considers Highnoon Laboratories to be Fairly Valued.
Key valuation signals for KAR:HINOON:
Return-on-Tangible-Asset: 20.69% (near median its 10-year median of 21.91)
GF Value™: ₨1,035.66 vs. price of ₨975.15 (5.8% below fair value)
Industry Position: 599% above the Drug Manufacturers median (#50 of 1006)
No single metric tells the full story. See the KAR:HINOON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Highnoon Laboratories Ltd is a company engaged in the manufacture, import, sale, and marketing of pharmaceutical and allied consumer products. It focuses on the alimentary tract and metabolism, antihistamines, anti-infectives, cardiovascular, endocrine, hematology, musculoskeletal, nervous system, parasitology, respiratory, and urinary. Its products include AIRTAL (Aceclofenac); ARIA (ketotifen); ARTECXCIN, and artrodar (diacerein). Its other products include Asthavent, AXESOME, Bezisox, Betatec, and many more.
96GF Score
Get the complete analysis for KAR:HINOON
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:HINOON has been successfully added to your 
